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Abstract 
The metabolic syndrome (MS) may be defined as the constellation of cardiovascular 
disease (CVD) risk factors that comprises obesity, type 2 diabetes, dyslipidemia, and 
hypertension. Recent evidences suggest that, primarily due to its high monounsaturated 
fatty acids (MUFAs) content, olive oil and omega-3 polyunsaturated fatty acids 
(PUFAs) could be useful as a dietary approach for MS management, with relevance in 
the postprandial state. Vitamin B3, as a major substrate for nicotinamide 
phosphoribosyltransferase (NAMPT), also constitutes a nutritional intervention strategy 
for the treatment of MS. NAMPT has been shown to exert activities of central 
importance to cellular energetics and innate immunity. Within the cell, NAMPT is the 
rate-limiting step in a salvage pathway of nicotinamide adenine dinucleotide (NAD+) 
biosynthesis. NAMPT has been shown to correlate with triglycerides in the fasting 
plasma, and a potential regulatory role for fatty acids on NAMPT expression has been 
proposed. Whether different dietary fatty acids, including olive oil as a source of 
MUFA, play a role in NAMPT excursions and in the NAMPT-dependent regulation of 
glucose and lipid metabolism and inflammation states remains to be solved. In general, 
the mechanisms that alter NAD+ metabolism probably include multiple processes, but 
the understandings of these mechanisms are currently very unclear and a considerable 
effort in this area is required before we know how changes in NAD+ metabolism 
influence physiology of glucose and lipid metabolism and how NAD+ metabolism 
might be manipulated for healing benefit by specific dietary fatty acids as a therapeutic 
treatment for MS. 	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Introduction 
Cardiovascular disease (CVD) is the first cause of death worldwide, with type 2 
diabetes (T2D) making up about 90% of the cases [1,2]. Incorporating a cluster of 
metabolic abnormalities, the metabolic syndrome (MS) was advocated by several 
organizations as a major predictor of CVD and T2D [3-6]. MS is characterized by four 
major traits: increased abdominal fat, hypertension, hyperglycemia, and dyslipidemia 
[7]. Lacks of habitual physical activity combined with diet contribute to increase the 
risk of CVD, and the development of MS in particular. The core components of the 
dyslipidemia in the MS, which most likely initiate CVD, are the “lipid triad” of high 
plasma triglycerides (TG), low levels of high-density lipoproteins (HDL), and a 
preponderance of small, dense low-density lipoproteins (LDL) at fasting [8]. 
Abnormally elevated postprandial (non-fasting) TG levels are also recognized as an 
important component for atherosclerosis, as first suggested by Zilversmit [9]. More 
recently, several studies have described abnormalities during the postprandial state in 
patients with coronary artery disease (CAD) [10] and have shown that non-fasting TG 
levels are independent predictors of CAD in multivariate analysis [11], even after 
adjustment for fasting TG or HDL levels in normolipidemic men. Exacerbated non-
fasting TG levels are often found in insulin-resistant subjects, denoting that 
hyperinsulinemia and/or decreased insulin sensitivity are involved in altered 
postprandial metabolism of dietary fats [12]. 
One of the current global recommendations to counteract disability and 
premature death resulting from CVD is to decrease the consumption of energy-dense 
diets, including high-fat foods enriched in saturated fatty acids (SFAs). The most 
effective replacement for SFAs in terms of risk factor outcomes for CVD is the 
monounsaturated fatty acids (MUFAs), and the polyunsaturated fatty acids (PUFAs) but 
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in much less importance [13]. In accordance, recent studies have demonstrated that 
olive oil, which is the only natural and most relevant source of MUFAs in the diet, 
when compared with butter, can postprandially limit TG excursions and buffer the 
pancreatic β-cell hyperactivity and peripheral insulin intolerance in subjects with 
normal [14] and high fasting [15] TG levels. 
Dietary fatty acids have received considerable attention for their ability to 
regulate inflammatory gene expression and secretion. It has been proposed that dietary 
fatty acids affect insulin resistance and inflammatory processes through the modulation 
of transcription factors such as NFκB and peroxisome proliferator-activated receptor 
gamma (PPARγ) [16, 17]. 
There is general agreement that increasing dietary SFA intake, especially in 
overweight or obese individuals, is associated with raised inflammatory markers [18], 
predominately by activating the toll-like receptor 4 (TLR4) pathway. TLR4 is expressed 
in both subcutaneous (SAT) and visceral (VAT) adipose tissues. SFAs serve as ligands 
for TLR4, inducing inflammatory responses in both adipocytes and macrophages 
through an increase of adipocytokine gene expression and production [19,20]. 
Moreover, SFA is associated with NFκB activation [21] which is a fundamental 
component underlying chronic inflammatory diseases such as atherosclerosis, 
rheumatoid arthritis, and MS [22]. Conversely, unsaturated fatty acid have well known 
anti-inflammatory effects, which range from the inhibition of the lipoxygenase and 
cyclooxygenase pathways, inhibition of TLR4 signaling, and PPARγ activation [23,24]. 
Thus, MUFAs can reproduce a number of the anti-inflammatory effects of TLR4 or 
induce TNF-α inhibition [25], which suggest that dietary MUFAs constitute an 
attractive nutritional approach for the treatment of MS. 
PPARγ is a fatty acid sensor that adapts β-cell mitochondrial function [26]. 
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Unsaturated fatty acids enhance mitochondrial oxidation levels in insulin-secreting 
cells, which protects against β-cell dysfunction [27]. In line it has been demonstrated 
that NAMPT (also known as visfatin or PBEF) improves insulin sensitivity and exerts 
its hypocholesterolemic effects at least partially through upregulation of the tyrosine 
phosphorylation of IRS-1 protein and the mRNA levels of PPARγ and SREBP-2 [28]. 
NAMPT is considered as a multifunctional adipokine involved in the regulation 
of different pathophysiological conditions. NAMPT is the rate-limiting enzyme in the 
NAD+ biosynthetic pathway starting from nicotinamide and essential when the cellular 
NAD+ pool is depleted, for example through poly-ADP-ribosylation during DNA repair 
and NAD+-dependent protein deacetylase activity. Two forms of NAMPT exist (Figure 
1), intracellular (iNAMPT) and extracellular (eNAMPT). While the function of 
iNAMPT as a NAD+ biosynthetic enzyme is well established, the physiological role of 
eNAMPT is still a matter of debate [29]. eNAMPT is positively secreted through a non-
classical secretory pathway by fully differentiated human adipocytes and hepatocytes. It 
has been suggested that eNAMPT exhibits robust, even higher NAD+ biosynthetic 
activity compared to iNAMPT and that NAD+ biosynthesis mediated by iNAMPT and 
eNAMPT plays a critical role in the regulation of glucose-stimulated insulin secretion in 
pancreatic β-cells. 
The observation that NAMPT has insulin-mimetic functions and is involved in 
the modulation of inflammation has raised the hypothesis that a dysregulation of the 
activity of this molecule may contribute to T2D and MS. Many research papers have 
been published on this topic, with controversial findings. Fasting NAMPT levels were 
found to be elevated in T2D patients, in women with gestational diabetes, and in 
extremely obese individuals (BMI >40), whereas fasting NAMPT levels were reduced 
by weight loss [30]. By contrast, other studies have failed to detect any correlation 
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between fasting NAMPT levels and body fat or insulin sensitivity [31]. In addition, 
NAMPT expression was not altered in a rodent model of the MS as compared with 
wild-type animals. Thus, the role of NAMPT in insulin resistance and diabetes is largely 
unknown and deserves further examination. 
Niacin (NA) or Vitamin B3 is a major substrate for NAMPT. In doses large 
enough to produce pharmacological effects, NA is a potent lipid-modifying agent with a 
broad spectrum of effects, including those aimed at attenuating the risks associated with 
low HDL, high LDL and TG levels in fasting plasma [32]. It is interesting to note that 
fasting TG levels strongly and positively correlated, and represented an independent 
factor associated, with NAMPT levels in healthy subjects and patients with obesity 
and/or T2D [30]. Moreover, fasting TG levels positively correlated with NAMPT 
mRNA expression in the VAT of obese subjects [31]. In contrast, there is also evidence 
of positive correlation between NAMPT and HDL levels, and of negative correlation 
between NAMPT and TG levels in the fasting state in a cohort of subjects with genetic 
predisposition for dyslipidemia [33], suggesting that NAMPT may be an indicator of 
beneficial lipid profile. In support of this notion, oral administration of NA significantly 
increased cellular NAD+ levels and had the ability to reduce fasting TG and LDL, 
whereas raising HDL [34]. These findings raise questions regarding of whether NA 
administration and the type of dietary fatty acids might be harmful or helpful NAMPT 
modulators to influence lipid homeostasis. At this stage, it is possible to argue that 
exogenous NA and the type of fatty acids in plasma TG may regulate NAMPT 
metabolism and function. This assumption substantiates the thought that exogenous TG 
in postprandial TRL may evoke pro- or anti-inflammatory signals in a fatty acid-
dependent fashion. Interestingly, a regulatory role for individual fatty acids, such as 
MUFAs (oleic acid), SFAs (palmitic acid), and omega-3 PUFAs (eicosapentaenoic 
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acid) on NAMPT gene expression has been described in 3T3-L1 murine adipocytes and 
monocytes [35,36]. In obese subjects, a recent cross-sectional study of associations 
between nutrient intake and fasting NAMPT levels has also demonstrated that MUFA 
intake, in the adjusted multivariate analysis, was the only independent predictor of 
fasting NAMPT levels [37]. 
Despite this considerable amount of data, whether different dietary fatty acids, 
including olive oil as a source of MUFAs and omega-3 PUFAs, play a role in NAMPT 
excursions and in the NAMPT-dependent regulation of glucose and lipid metabolism 
and inflammation in the fed and postprandial states remains to be solved. 
In general, the mechanisms that alter NAD+ metabolism probably include 
multiple processes, but the understandings of these mechanisms are currently very 
unclear and a considerable effort in this area is required before we know how changes in 
NAD+ metabolism influence physiology of glucose and lipid metabolism and how 
NAD+ metabolism might be manipulated for healing benefit by specific dietary fatty 
acids.  
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Legend to Figure 
 
Figure 1. Model of putative modes of action for NAMPT to affect cell metabolism 
adaptaed from Garten et al. [29]. NAMPT functions as an intra- and extracellular 
NAD+ biosynthetic enzyme. NAMPT catalyzes the formation of nicotinamide 
mononucleotide (NMN) from nicotinamide (NAM). NMN is subsequently converted to 
NAD+ by three organelle-specific isoforms of nicotinamide mononucleotide 
adenylyltransferase (Nmnat1–3). Intracellularly, NAMPT has been shown to be located 
in different cellular compartments. It affects the function of NAD+-degrading enzymes 
by raising cellular NAD+ levels and consequently influences the regulation of 
metabolism and stress resistance through sirtuins (Sirt1–7) and other NAD+-consuming 
enzymes, such as poly(ADP-ribose)polymerase-1 (PARP-1). The NAD+ metabolism of 
(a) mitochondria and (b) nucleus is possibly influenced by transport of NAD+ 
metabolites from and to the cytoplasm. (c) Extracellularly, NAMPT produces 
nicotinamide mononucleotide (NMN), which might act in an autocrine/paracrine 
fashion and/or be transported to other target tissues, where it acts on glucose-stimulated 
insulin secretion in pancreatic β-cells and potentially elicits other biological responses. 
(d) Possibly, NAMPT also functions as a cytokine by binding to and activating an 
unidentified receptor. 
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